| Literature DB >> 17719147 |
I A F B Silveira1, R C Bastos, M S Neto, A P Laranjeira, E F Assis, S A R Fernandes, M L Leal, W C Silva, C-H Lee, C E Frasch, J M Peralta, E Jessouroun.
Abstract
The steps to produce, purify and control an immunogenic Brazilian conjugate vaccine against group C meningococcus (MenCPS-TT) using hydrazide-activated tetanus toxoid were developed. The conjugation methodology reduced the reaction time easily allowing scale-up. One freeze-dried pilot vaccine lot purified by tangential filtration, showed satisfactory quality control results including safety and stability. The pilot vaccine was immunogenic in mice in a dose-dependent fashion generating a 10-20-fold rise in IgG response in mice. The vaccine also induced high bactericidal titers. Vaccine concentrations of 1 and 0.1 microg showed higher avidity indices, suggesting induction of immunologic memory. These results support initiation of Phase I clinical studies with the MenCPS-TT conjugate vaccine.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17719147 DOI： 10.1016/j.vaccine.2007.07.037
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641